Microhemodynamic consequences of tumor angiogenesis targeting using the tyrosine kinase inhibitor SU11248

被引：0
|
作者：
Czabanka, M.
Erber, R.
Vinci, M.
Ullrich, A.
Vajkoczy, P.
机构：
[1] Univ Heidelberg, Klinikum Mannheim, Dept Neurosurg, Mannheim, Germany
[2] Max Planck Inst Biochem, D-82152 Martinsried, Germany
来源：
JOURNAL OF VASCULAR RESEARCH | 2006年 / 43卷 / 06期
关键词：
D O I：
暂无
中图分类号：
Q4 [生理学];
学科分类号：
071003 ;
摘要：
引用
收藏
页码：564 / 564
页数：1
相关论文
共 50 条
  • [31] Receptor tyrosine kinase activity and apoptosis in gastrointestinal stromal tumours: A pharmacodynamic analysis of response to sunitinib malate (SU11248) therapy.
    Davis, D
    Heymach, J
    McConkey, D
    Desai, J
    George, S
    Jackson, J
    Bello, C
    Baum, C
    Shalinsky, D
    Demetri, G
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9027S - 9027S
  • [32] The multitargeted kinase inhibitor sunitinib malate (SU11248): soluble protein biomarkers of pharmacodynamic activity in patients with metastatic renal cell cancer
    DePrimo, S.
    Bello, C.
    Smeraglia, J.
    Shalinsky, D.
    Freddo, J.
    Baum, C.
    Rini, R.
    Michaelson, M.
    Motzer, R.
    Spinella, D.
    EJC SUPPLEMENTS, 2005, 3 (02): : 420 - 420
  • [33] Tyrosine kinase inhibitors, such as TAK-285, GW572016 or SU11248, protect or damage the heart based on their ability to activate AMPK
    Shell, S. A.
    Wappel, R. L.
    Trusk, P.
    Ohta, Y.
    Klohs, W.
    Bacus, S. S.
    EJC SUPPLEMENTS, 2008, 6 (12): : 27 - 27
  • [34] SU11248, an oral multi-kinase inhibitor, shows anti proliferative and antitumoral activity in a human medullary thyroid carcinoma model
    Broutin, S.
    Ameur, N.
    Gug, F.
    Galons, H.
    Dupuy, C.
    Schlummberger, M.
    Bidart, J. -M.
    HORMONE RESEARCH, 2007, 68 : 39 - 39
  • [35] Inhibition of Tumor growth and Angiogenesis in Ovarian cancer Xenograftmodel by SU 11248 (Sunitinib)
    Bauerschlag, D.
    Schem, C.
    Pecks, U.
    Weigel, M.
    Jonat, W.
    Maass, N.
    Meinhold-Heerlein, I.
    ONKOLOGIE, 2010, 33 : 111 - 111
  • [36] Tyrosine kinase inhibitor SU6668 inhibits peritoneal dissemination of gastric cancer via suppression of tumor angiogenesis
    Tokuyama, J
    Kubota, T
    Saikawa, Y
    Yoshida, M
    Furukawa, T
    Otani, Y
    Kumai, K
    Kitajima, M
    ANTICANCER RESEARCH, 2005, 25 (1A) : 17 - 22
  • [37] A novel vascular endothelial growth factor receptor 2 inhibitor, SU11248, suppresses choroidal neovascularization in vivo
    Takahashi, Hidenori
    Obata, Ryo
    Tamaki, Yasuhiro
    JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2006, 22 (04) : 213 - 218
  • [38] SU11248 (sunitinib) directly inhibits the activity of mammalian 5′-AMP-activated protein kinase (AMPK)
    Laderoute, Keith R.
    Calaoagan, Joy M.
    Madrid, Peter B.
    Klon, Anthony E.
    Ehrlich, Paula J.
    CANCER BIOLOGY & THERAPY, 2010, 10 (01) : 68 - 76
  • [39] Mechanism of action and biomarker studies of SU11248, a selective inhibitor of split kinase domain receptor tyrosine kinases (including VEGF receptors, PDGF receptors, c-Kit, and Flt3)
    Potapova, O
    Laird, A
    Nannini, M
    Li, G
    Moss, K
    Cherrington, J
    Mendel, D
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S61 - S61
  • [40] Sunitinib (SUTENT, SU11248) Suppresses Tumor Growth and Induces Apoptosis in Xenograft Models of Human Hepatocellular Carcinoma
    Huynh, H.
    Ngo, V. C.
    Choo, S. P.
    Poon, D.
    Koong, H. N.
    Thng, C. H.
    Toh, H. C.
    Zheng, L.
    Ong, L. C.
    Jin, Y.
    Song, I. C.
    Chang, A. P. C.
    Ong, H. S.
    Chung, A. Y. F.
    Chow, P. K. H.
    Soo, K. C.
    CURRENT CANCER DRUG TARGETS, 2009, 9 (06) : 738 - 747
12345